<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01587586</url>
  </required_header>
  <id_info>
    <org_study_id>A11-201</org_study_id>
    <nct_id>NCT01587586</nct_id>
  </id_info>
  <brief_title>Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With HCV Genotype 1 Infection</brief_title>
  <official_title>An Open-label, Randomized, Active Control Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of P1101 + Ribavirin in Treatment-Naïve Subjects With HCV Genotype 1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaEssentia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaEssentia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objectives:

      The purpose of this study is to determine and compare the sustained virologic response (SVR,
      undetectable HCV RNA at Follow up week 24 (FW24)) across treatment groups.

      To determine and compare the safety and tolerability of P1101 + Ribavirin across treatment
      groups.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Virologic Response</measure>
    <time_frame>Follow up week 24 across treatment groups</time_frame>
    <description>Percentage of subjects with sustained virologic response (SVR, undetectable HCV RNA at follow up week 24) across treatment groups.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">208</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Pegasys</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegasys(subcutaneous injection)+Ribavirin, multiple doses(48)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P1101, 48 doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>P1101(subcutaneous injection)with Ribavirin, multiple doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P1101, 24 doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>P1101(subcutaneous injection)+Ribavirin, multiple doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P1101, 12 doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>P1101(subcutaneous injection)+Ribavirin, multiple doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegasys</intervention_name>
    <description>48 doses, solution, 48 weeks</description>
    <arm_group_label>Pegasys</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>P1101, 48 doses</intervention_name>
    <description>48 doses, solution, 48 weeks</description>
    <arm_group_label>P1101, 48 doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>P1101, 24 doses</intervention_name>
    <description>24 doses, solution, 48 weeks</description>
    <arm_group_label>P1101, 24 doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>P1101, 12 doses</intervention_name>
    <description>12 doses, solution, 48 weeks</description>
    <arm_group_label>P1101, 12 doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults ≥18 years of age ( ≥20 years for subjects enrolled in Taiwan);

          -  Confirmed diagnosis of chronic hepatitis C (CHC) virus genotype 1 infection;

          -  Compensated liver disease: with normal or elevated ALT/AST, no evidence of cirrhosis
             or portal hypertension as identified by ultrasound or any other procedures within 6
             months before study entry;

          -  Treatment naïve

          -  No other form of chronic liver disease apart from chronic hepatitis C infection;

          -  Hematology and renal biochemistry should be in definded ranges;

          -  Be able to attend all scheduled visits and to comply with all study procedures;

          -  Be able to provide written informed consent.

        Exclusion Criteria:

          -  Positive test for hepatitis B surface antigen (HBsAg) or human immunodeficiency virus
             (HIV) at screening;

          -  Pregnancy or, in women of child-bearing potential or in spouses of such women,
             unwillingness or inability to practice adequate contraception;

          -  Inability to comprehend the written consent form;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ding-Shinn Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ting-Fang Wang, MS/MHA</last_name>
    <phone>+886 2 26557688</phone>
    <phone_ext>7814</phone_ext>
    <email>tingfang_wang@pharmaessentia.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ching-Leou Teng, Ph.D.</last_name>
    <phone>+886 2 26557688</phone>
    <phone_ext>7801</phone_ext>
    <email>chingleou_teng@pharmaessentia.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2012</study_first_submitted>
  <study_first_submitted_qc>April 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2012</study_first_posted>
  <last_update_submitted>April 27, 2012</last_update_submitted>
  <last_update_submitted_qc>April 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C, Chronic</keyword>
  <keyword>Interferon-alpha</keyword>
  <keyword>Hepatitis C Virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

